To evaluate whether platelet rich plasma treatment improve pregnancy rate

A comparative evaluation of novel sub-endometrial and intrauterine platelet rich plasma treatment for women with recurrent implantation failure - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/05/025438

Enrollment

296

Registered

2020-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N978- Female infertility of other origin

Interventions

Intervention1: platelet rich plasma: group 1 : PRP as injection into subendometrial space in the uterine cavity. Control Intervention1: group 2 - PRP as infusion into uterine cavity .: group 3 - no

Eligibility

Inclusion criteria

Inclusion criteria: Those with history of recurrent implantation failures ( more than 3 attempts ) undergoing frozen embryo transfer

Exclusion criteria

Exclusion criteria: BMI > 30 kg/m2, Congenital uterine cavity anomalies, Adenomyosis, Fibroid, Intrauterine adhesions, Untreated hydrosalpinx and Endometrial polyps, Poor ovarian responders as per Bologna criteria, PGT-A embryos, Women undergoing FET with thin endometrium <8mm, Antiphospholipid antibody positive, Uncontrolled endocrine and hematologic dysfunction, Severe male factor infertility, Difficult embryo transfer, Poor quality embryos in the index cycle, Couple with genetic and chromosomal abnormalities

Design outcomes

Primary

Measure	Time frame
Ongoing Pregnancy Or Live Birth RateTimepoint: after 20 weeks	—

Secondary

Measure	Time frame
Clinical Pregnancy Rate ,Miscarriage RateTimepoint: at 6 weeks , at 20 weeks	—

Countries

India

Contacts

Public ContactDr Noushin Abdul Majiyd

Craft Hospital And Research Centre

drnoshinashraf@gmail.com9544240002

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026